Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CCR8 | P51685 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.43 |
| ▸ | METAP1 | P53582 | 3/20 | 0.43 |
| ▸ | ACP1 | P24666 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3782691 | 0.84 | CYP3A4 (0.52) | TGFBR1KDM4EMETAP1ACP1CYP3A4 | |
| SCHEMBL2714051 | 0.79 | ACHE (0.57) | HTR3ACCR1CCR5CCR8SMN1; SMN2 | |
| SCHEMBL1238925 | 0.73 | CYP1A2 (0.60) | HTR3ASMN1; SMN2LMNAMAPT | |
| SCHEMBL4272819 | 0.71 | SLC2A1 (0.56) | HTR3ASMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7853202 | 0.70 | CCR1 (0.61) | CCR1CCR5CCR8 | |
| SCHEMBL198098 | 0.70 | CCR1 (0.81) | CCR1CCR5CCR8ALDH1A1KDM4E | |
| SCHEMBL181893 | 0.70 | CCR1 (1.00) | CCR1CCR5CCR8ALDH1A1LMNA | |
| SCHEMBL29397106 | 0.70 | CCR1 (1.00) | CCR1CCR5CCR8ALDH1A1LMNA | |
| SCHEMBL23052940 | 0.70 | MEN1 (0.59) | HTR3ASMN1; SMN2ALDH1A1KDM4EMAPT | |
| SCHEMBL4500702 | 0.69 | HTR1A (0.63) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | HTR3A 3130/4885CCR1 1153/4885CCR5 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.